<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008995</url>
  </required_header>
  <id_info>
    <org_study_id>CR016318</org_study_id>
    <secondary_id>C0743T23</secondary_id>
    <secondary_id>CR016318</secondary_id>
    <nct_id>NCT01008995</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Chinese Subjects With Moderate to Severe Plaque-type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centocor, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy (good or bad effects) and safety of
      ustekinumab in the treatment of patients with moderate to severe psoriasis in China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, 220 patients will be divided into two groups randomly (by chance), like
      flipping a coin. Each group will receive a different treatment. The results for each group
      are compared to each other. There are 2 treatment groups in this study, Group 1 and Group 2.
      Group 1 will receive placebo at Weeks 0 and 4, ustekinumab 45 mg at Weeks 12 and 16. Group 2
      will receive ustekinumab 45 mg at Weeks 0, 4, and 16 and placebo at Week 12. All patients in
      the study will eventually receive ustekinumab after Week 12. The patients will be in the
      study for about 36 weeks, with study visit approximately 10 times. Effectiveness evaluations
      will be conducted throughout the study and include the Psoriasis Area and Severity Index
      (PASI), Physician's Global Assessment (PGA) and Dermatology Life Quality Index (DLQI). Safety
      assessments will also be performed throughout the study and include obtaining and evaluating
      laboratory tests, vital signs (e.g., blood pressure) and the occurrence and severity of
      adverse events. GROUP 1: Placebo at Weeks 0 and 4, ustekinumab 45 mg at Weeks 12 and 16.
      GROUP 2: Ustekinumab 45 mg at Weeks 0, 4, and 16. Placebo at Week 12
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Patients Who Achieved at Least a 75% Improvement in PASI (Psoriasis Area and Severity Index) From Baseline at Week 12.</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>Scores could range from 0 (mild) to 72 (severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients With a Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Dermatology Life Quality Index (DLQI) From Baseline at Week 12.</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>Scores could range from 0 to 30. A lower DLQI score represents better quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">322</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo Subcutaneous injection at Week 0 and 4,ustekinumab 45 mg subcutaneous injection at Week 12 and 16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo Subcutaneous injection at Week 12,ustekinumab 45 mg subcutaneous injection at Week 0 4 and 16</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subcutaneous injection at Week 0 and 4</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ustekinumab</intervention_name>
    <description>45 mg subcutaneous injection at Week 12 and 16</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subcutaneous injection at Week 12</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ustekinumab</intervention_name>
    <description>45 mg subcutaneous injection at Week 0, 4 and 16</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be of Chinese ancestry

          -  Have had a diagnosis of plaque-type psoriasis at least 6 months prior to study start

          -  Have plaque-type psoriasis covering at least 10% of total BSA at screening and at the
             time of study start

          -  Have a Psoriasis Area and Severity Index (PASI) score of 12 or greater at study start

          -  Must be candidates for phototherapy or systemic treatment of psoriasis (either naive
             or history of previous treatment)

        Exclusion Criteria:

          -  Currently have nonplaque forms of psoriasis

          -  Have current drug-induced psoriasis

          -  Have used any investigational drug within the previous 4 weeks

          -  Have used any biologic within the previous 3 months

          -  Be known to be infected with human immunodeficiency virus (HIV), hepatitis B virus
             (HBV), hepatitis C virus (HCV), or syphilis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Centocor, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Centocor, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2009</study_first_submitted>
  <study_first_submitted_qc>November 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2009</study_first_posted>
  <results_first_submitted>August 15, 2012</results_first_submitted>
  <results_first_submitted_qc>August 15, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 14, 2012</results_first_posted>
  <last_update_submitted>October 17, 2013</last_update_submitted>
  <last_update_submitted_qc>October 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>asian patients</keyword>
  <keyword>Chinese</keyword>
  <keyword>ustekinumab</keyword>
  <keyword>CNTO 1275</keyword>
  <keyword>Stelara</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo (CP)</title>
          <description>Controlled period (Week 0-12) - Placebo Group</description>
        </group>
        <group group_id="P2">
          <title>Ustekinumab 45 mg (CP)</title>
          <description>Controlled period (Week 0-12) - Ustekinumab 45 mg Group</description>
        </group>
        <group group_id="P3">
          <title>Placebo -&gt; Ustekinumab 45 mg (After CP)</title>
          <description>After controlled period (Week 12-36) – receiving Placebo at Weeks 0 and 4 -&gt; receiving ustekinumab 45 mg at Week 12 and Week 16</description>
        </group>
        <group group_id="P4">
          <title>Ustekinumab 45 mg (After CP)</title>
          <description>After controlled period (Week 12-36) – receiving ustekinumab 45 mg at Weeks 0 and 4 -&gt; receiving placebo at Week 12 and ustekinumab 45 mg at Week 16</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Controlled Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="160"/>
                <participants group_id="P3" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Control Period.</participants>
                <participants group_id="P4" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Control Period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="157"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Controlled Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to after Control Period.</participants>
                <participants group_id="P2" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to after Control Period.</participants>
                <participants group_id="P3" count="158">1 placebo participant discontinued after completing the CP and did not receive ustekinumab 45 mg.</participants>
                <participants group_id="P4" count="157">2 participants discontinued in CP, had follow-up, and are among frequent and serious adverse events.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="156"/>
                <participants group_id="P4" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo (CP)</title>
          <description>Controlled period (Week 0-12) - Placebo Group</description>
        </group>
        <group group_id="B2">
          <title>Ustekinumab 45 mg (CP)</title>
          <description>Controlled period (Week 0-12) - Ustekinumab 45 mg Group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="162"/>
            <count group_id="B2" value="160"/>
            <count group_id="B3" value="322"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.2" spread="12.21"/>
                    <measurement group_id="B2" value="40.1" spread="12.36"/>
                    <measurement group_id="B3" value="39.7" spread="12.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Patients Who Achieved at Least a 75% Improvement in PASI (Psoriasis Area and Severity Index) From Baseline at Week 12.</title>
        <description>Scores could range from 0 (mild) to 72 (severe).</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>All participants were analyzed according to the treatment group to which they were randomized, regardless of the treatment they actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (CP)</title>
            <description>Controlled period (Week 0-12) - Placebo Group</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 45 mg (CP)</title>
            <description>Controlled period (Week 0-12) - Ustekinumab 45 mg Group</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Who Achieved at Least a 75% Improvement in PASI (Psoriasis Area and Severity Index) From Baseline at Week 12.</title>
          <description>Scores could range from 0 (mild) to 72 (severe).</description>
          <population>All participants were analyzed according to the treatment group to which they were randomized, regardless of the treatment they actually received.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference between ustekinumab 45 mg and placebo for the primary endpoint at a significance level of 0.05. Power calculations were based on two sample size assumptions: 220 (1:1 ratio) and 320 participants (1:1 ratio). Simulation studies evaluated the power to detect a treatment difference between ustekinumab 45 mg group and placebo using a CMH test stratified by baseline weight [&lt;=65 kg vs &gt; 65 kg). The power was &gt;99% for both sample size assumptions.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The study was designed to maintain a Type I error of 0.05 or less for the primary analysis.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by baseline weight [≤ 65kg vs &gt; 65 kg)].</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients With a Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>All participants were included and analyzed according to their randomized treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (CP)</title>
            <description>Controlled period (Week 0-12) - Placebo Group</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 45 mg (CP)</title>
            <description>Controlled period (Week 0-12) - Ustekinumab 45 mg Group</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients With a Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12</title>
          <population>All participants were included and analyzed according to their randomized treatment group.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference between ustekinumab 45 mg and placebo at a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment was made and nominal p-value was reported.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by baseline weight [≤ 65kg vs &gt; 65 kg)].</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Dermatology Life Quality Index (DLQI) From Baseline at Week 12.</title>
        <description>Scores could range from 0 to 30. A lower DLQI score represents better quality of life.</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Analysis was based on the subset of participants with evaluable measurements according to their randomized treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (CP)</title>
            <description>Controlled period (Week 0-12) - Placebo Group</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 45 mg (CP)</title>
            <description>Controlled period (Week 0-12) - Ustekinumab 45 mg Group</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Dermatology Life Quality Index (DLQI) From Baseline at Week 12.</title>
          <description>Scores could range from 0 to 30. A lower DLQI score represents better quality of life.</description>
          <population>Analysis was based on the subset of participants with evaluable measurements according to their randomized treatment group.</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="6.63"/>
                    <measurement group_id="O2" value="-9.3" spread="7.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference between ustekinumab 45 mg and placebo at a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment was made and nominal p-value was reported.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Analysis of variance on van der Waerden normal scores (Conover, 1980) with treatment and baseline weight (≤ 65kg vs &gt; 65 kg) as factors in the model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>One patient from the 'Placebo (CP)' group was randomized, but never received any treatment. Therefore, he was not included in any safety analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (CP)</title>
          <description>Controlled period (Week 0-12) - Placebo Group</description>
        </group>
        <group group_id="E2">
          <title>Ustekinumab 45 mg (CP)</title>
          <description>Controlled period (Week 0-12) - Ustekinumab 45 mg Group</description>
        </group>
        <group group_id="E3">
          <title>Placebo -&gt; Ustekinumab 45 mg (After CP)</title>
          <description>After controlled period (Week 12-36) – receiving Placebo at Weeks 0 and 4 -&gt; receiving ustekinumab 45 mg at Week 12 and Week 16</description>
        </group>
        <group group_id="E4">
          <title>Ustekinumab 45 mg (After CP)</title>
          <description>After controlled period (Week 12-36) – receiving ustekinumab 45 mg at Weeks 0 and 4 -&gt; receiving placebo at Week 12 and ustekinumab 45 mg at Week 16</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Research</name_or_title>
      <organization>Janssen R&amp;D US</organization>
      <phone>1 215-793-7646</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

